

**This is the author's final version of the contribution published as:**

**Krause, S., Goss, K.-U.** (2018):

*In vitro–in vivo* extrapolation of hepatic metabolism for different scenarios - a toolbox  
*Chem. Res. Toxicol.* **31** (11), 1195 – 1202

**The publisher's version is available at:**

<http://dx.doi.org/10.1021/acs.chemrestox.8b00187>




10 **ABSTRACT**

11 The extrapolation of metabolism data from *in vitro* experiments to *in vivo* clearances can  
12 provide useful information in the fields of pharmacokinetics and toxicokinetics. Depending on  
13 the purpose, different toxicokinetic models are used and these different models require the *in*  
14 *vitro* metabolic information in different forms. In this study, a comprehensive toolbox for *in*  
15 *vitro* – *in vivo* extrapolation (IVIVE) of hepatic metabolism is presented addressing a variety  
16 of different extrapolation goals: extrapolation to hepatic blood clearance, extrapolation to  
17 organ clearance, extrapolation to whole-body clearance and extrapolation to clearance at the  
18 level of hepatocytes. The use of the extrapolated clearances for calculation of extraction  
19 efficiencies and the use in physiologically based pharmacokinetic models are discussed.  
20 Furthermore, a sensitivity analysis demonstrates which parameters affect the accuracy of the  
21 extrapolation results the most and the presented extrapolation procedure is evaluated by  
22 comparison to experimental data from perfused liver experiments.

23

24 TOC graphic (?)

*in vitro* – *in vivo* extrapolation of biotransformation kinetics



25

26

27

## 28 INTRODUCTION

29 There is a broad interest in pharmacology and toxicology on kinetic information about hepatic  
30 metabolism of organic chemicals in organisms. In the context of the Replace, Reduce and  
31 Refine targets (3Rs) for the use of animals in scientific research this information should  
32 preferably come from *in vitro* assays. An extrapolation step is needed in order to use this  
33 kinetic *in vitro* information in any kind of toxicokinetic model. This *in vitro* – *in vivo*  
34 extrapolation (IVIVE) has to account for the different amounts of metabolically active  
35 components (hepatocytes, microsomal protein or S9 material) *in vitro* and *in vivo* and it has to  
36 account for the different environment in both cases. This extrapolation can also contain  
37 information on additional kinetic effects on the hepatic metabolism such as blood flow  
38 limitation in the liver.

39 The first equations offered for this extrapolation challenge have been presented in the 1970s  
40 in the pharmacology literature <sup>1</sup>. However, a systematic discrepancy between predicted and  
41 observed *in vivo* metabolic clearance has frequently been found <sup>2-5</sup>. This and the fact that most  
42 published extrapolation schemes focus on one specific scenario <sup>4, 6-8</sup> while other relevant  
43 IVIVE scenarios are not covered led us to revisit and explore the mathematics that are  
44 required for a consistent and comprehensive IVIVE scheme.

45 This work is structured as follows: we first state the commonly accepted assumptions and  
46 boundary conditions that are needed for a stringent problem definition. In a next section, we  
47 summarize the various relevant scenarios of IVIVE of metabolic information and their  
48 applications in the context of pharmaco- and toxicokinetics. We then try to give a short  
49 literature overview concerning IVIVE schemes that have already been suggested for single  
50 specific scenarios. Afterwards we present the mathematics that solves the various  
51 extrapolation tasks introduced in the first section. This is followed by a sensitivity analysis for  
52 the impact that various variables have on the extrapolation result. Finally we apply our

53 extrapolation scheme to published data from a perfused liver experiment and discuss the  
54 results.

55

### 56 **Defining the assumptions for IVIVE**

57 A clear definition of the assumptions and boundary conditions forming the basis of the IVIVE  
58 is needed as a starting point. For the *in vitro* experiments this can be summarized as follows:

59 The *in vitro* assay is assumed to be well-stirred with instantaneous sorption equilibrium  
60 between all its parts at all times. Any sorption equilibria (e.g. between hepatocytes and water)  
61 can be described by known equilibrium partition coefficients:


$$K_{phase1/phase2} = \frac{C_{phase1}}{C_{phase2}}$$

62 where  $C_{phase}$  (g/mL<sub>phase</sub>) refers to the equilibrium concentration in the corresponding total  
63 phase and the unit of  $K_{phase1/phase2}$  is mL<sub>phase2</sub>/mL<sub>phase1</sub>. The metabolically active  
64 components (hepatocytes, microsomal protein or S9 material) in the *in vitro* assay are  
65 assumed to behave the same as those *in vivo*. Based on measured concentration-time curves,  
66 the *in vitro* clearance in the assay can be determined. By definition, the reported clearance  
67 value refers to the assay volume that is cleared of the chemical per unit time<sup>9</sup>. Accordingly,  
68 the unit of the *in vitro* clearance in the assay ( $CL_{assay}$ ) is ml of total assay volume per unit time  
69 (mL<sub>assay</sub>/min).

70

### 71 **Overview of the manifold extrapolation goals**

72 The goals of the IVIVE process using the measured clearance in the assay,  $CL_{assay}$  (in  
73 mL<sub>assay</sub>/min), can be manifold. Figure 1 gives an overview of the different extrapolation goals  
74 that will be discussed in this text:



75  
76

Figure 1: Overview of various extrapolation goals.

- 77 I. Extrapolation to a whole organism,  $CL_{organism}$  (in  $mL_{organism}/min$ ), that is assumed to be  
78 well-stirred with an instantaneous sorption equilibrium.
- 79 II. Extrapolation to the liver as a well-stirred organ with instantaneous sorption  
80 equilibrium. Here, a subdivision is needed:
- 81 IIa) Extrapolation to the actual organ clearance,  $CL_{liver}$  ( $mL_{liver}/min$ ). This  $CL_{liver}$  serves  
82 as an intermediate step for extrapolation to IIb).
- 83 IIb) Extrapolation to a clearance of blood that passes through a well-stirred liver with  
84 instantaneous sorption equilibrium within the organ. This hepatic blood clearance  
85 additionally accounts for potential blood flow limitation of liver metabolism. It is  
86 noteworthy that this is the only case where clearance does not refer to the volume of  
87 the well-stirred compartment in which the metabolic transformation takes place but to  
88 another, external volume; here blood. For better discrimination, we introduce the

89 variable  $CL_{blood}$  (mL<sub>blood</sub>/min) for this blood clearance. Note, though, that this hepatic  
90 blood clearance is often called ‘hepatic clearance’ ( $CL_{hep}$  or  $CL_H$ ) in the literature.

91 III Extrapolation to hepatocytes as well–stirred cells with instantaneous sorption  
92 equilibrium within the cells. This hepatocyte clearance,  $CL_{hepatocytes}$  (mL<sub>hepatocyte</sub>/min),  
93 reflects the capacity of hepatocytes to transform the compound that they contain.

94

### 95 **Applications of the extrapolated clearances**

96 I. A whole-body clearance,  $CL_{organism}$ , based on a one-compartment organism model  
97 is useful information as such. In environmental sciences, the whole-body clearance  
98 is used as an input parameter for prediction of bioconcentration factors.

99 IIa) Liver clearance,  $CL_{liver}$ , is a required input parameter for multi-compartment  
100 toxicokinetic models that eventually allow to calculate whole-body clearance but  
101 also other information such as peak concentration in blood and area under the  
102 curve (AUC) or explicit concentration time curves in all considered  
103 compartments/organs (see Stadnicka-Michalak et al. <sup>10</sup> as an example). Blood  
104 circulation is represented explicitly by such models so that blood flow limitation of  
105 hepatic metabolism is implicitly covered.

106 IIb) Hepatic blood clearance can be used to calculate the extraction efficiency of the  
107 liver under steady-state conditions <sup>1,9</sup>. In contrast to liver clearance, this extraction  
108 efficiency  $E$  is a measure of how efficient blood is cleared from a chemical when  
109 passing the liver.  $E$  considers potential limitations by blood flow and is defined as  
110 the concentration difference between inflowing and outflowing blood relative to  
111 the concentration in inflowing blood.

112 III. Hepatocyte clearance is a required input information for more complex  
113 toxicokinetic models in which the liver is not treated as a single compartment, but  
114 divided up into liver blood, hepatocytes and other liver tissue. Such a detailed

115 approach allows to cover additional kinetic processes with potential impact on the  
116 final metabolism rate such as: active uptake or excretion in/out of hepatocytes by  
117 transporter proteins, permeability limitations between blood and the hepatocytes  
118 and slow desorption kinetics of the chemical from albumin in the blood <sup>11</sup>.  
119 Hepatocyte clearance is also needed if one wants to calculate an extraction  
120 efficiency for the liver that accounts for these additional kinetic processes. In <sup>12</sup> we  
121 have shown how all these additional limitations can be built into a formula for the  
122 extraction efficiency under steady-state conditions.

123

#### 124 **IVIVE procedures in the literature**

125 There is a vast amount of literature on IVIVE and a complete review is not possible here. We  
126 therefore focus this overview on a few exemplary papers that we found to be the most  
127 influential or that seem to represent the state of the art in the field.

128 First attempts to predict *in vivo* hepatic metabolism from *in vitro* experiments were made  
129 more than 40 years ago <sup>1</sup>. Their goal was the prediction of the hepatic extraction efficiency via  
130 extrapolation to the hepatic blood clearance (case IIb) above). In the 1990s, this extrapolation  
131 procedure was refined regarding the implementation of scaling factors and the consideration  
132 of nonspecific binding by introducing binding corrections <sup>6, 13</sup>. Recently, novel methods for  
133 binding corrections have been published considering ionization of the metabolized compound  
134 and protein-facilitated uptake <sup>14, 15</sup>. The common goal of all these IVIVE-methods remained  
135 the extrapolation to the hepatic clearance of blood including blood flow limitation (i.e. case  
136 IIb) above). Extrapolation schemes for the other scenarios from our list above are not  
137 explicitly covered in the literature. In the following, we derive a mathematic formalism  
138 addressing all the scenarios introduced above.

139

140

141 **METHODS**

142 **Extrapolation to clearance in well-stirred organism, liver or hepatocytes**

143 The general idea of the extrapolation procedure is as follows: There is an intrinsic  
144 metabolizing capacity of the hepatocytes, microsomes or S9 material for the studied chemical.  
145 The assay and all other systems to which we want to extrapolate (scenarios I to III) have this  
146 intrinsic capacity or clearance in common. An extrapolation scheme has to extract this  
147 information on intrinsic clearance out of the assay experiments and can then apply it to any  
148 new scenario or system. This intrinsic clearance must be normalized to the available amount  
149 of viable hepatocytes, S9 material or microsomes.

150 The following step-by-step derivation follows this general idea: Based on the determined *in*  
151 *vitro* clearance in the assay  $CL_{assay}$  (mL<sub>assay</sub>/min), the decline of total mass ( $M_{in\ assay}^{total}$ ) of a  
152 chemical in the assay can be described as a function of time by the following differential  
153 equation:

$$\frac{dM_{in\ assay}^{total}}{dt} = \frac{dC_{in\ assay}^{total}V_{assay}^{total}}{dt} = CL_{assay} C_{in\ assay}^{total} \quad (1)$$

154 with  $C_{in\ assay}^{total}$  (in g/mL<sub>assay</sub>) as the total chemical concentration in the assay. This is the  
155 starting point of any IVIVE procedure. It is obvious that the clearance measured in this way  
156 must be a function of the amount of metabolic active component (hepatocytes, S9 material or  
157 microsomal protein) present in the assay, or, in other words, the assay clearance actually  
158 follows a pseudo-first order kinetics. The first step towards extrapolation must therefore be to  
159 normalize clearance to the amount of metabolic active component because the amount of  
160 metabolic active component at the endpoint of our extrapolation (e.g. in the liver) will differ  
161 from the one in the assay. This normalization is done by expanding the equation by the  
162 amount of metabolically active component  $N_{in\ assay}^{hep/mp}$  (number of hepatocytes or mg of S9  
163 material or microsomal protein in the assay):

$$\frac{dM_{in\ assay}^{total}}{dt} = \frac{CL_{assay}}{N_{in\ assay}^{hep/mp}} * C_{in\ assay}^{total} * N_{in\ assay}^{hep/mp} \quad (2)$$

164 This new expression is still specific for the assay because the clearance refers to the total  
 165 assay concentration. Note that the term  $\frac{CL_{assay}}{N_{in\ assay}^{hep/mp}}$  is equivalent to what is often called *in vitro*  
 166 intrinsic clearance in the literature<sup>5, 14</sup>. In the next step we now have to change this specific  
 167 reference into one that is universal and can be used in all systems. It is generally accepted that  
 168 only the unbound concentration in the aqueous parts of any system is directly available to  
 169 enzymatic transformation. Consequently, a universal clearance should refer to the water  
 170 volume that is cleared from the unbound chemical by the available hepatocytes, S9 material or  
 171 microsomes. This is achieved by transforming the equation such that it now refers to the  
 172 unbound concentration in the water of the assay ( $C_{assay}^{unbound}$ , in mg/mL<sub>water</sub>). For doing so, we  
 173 replace  $C_{in\ assay}^{total}$  by  $\frac{C_{assay}^{unbound} V_{assay}^{water}}{f_{assay}^{unbound} V_{assay}^{total}}$ :

$$\frac{dM_{in\ assay}^{total}}{dt} = \frac{CL_{assay}}{N_{in\ assay}^{hep/mp}} * \frac{V_{assay}^{water}}{f_{assay}^{unbound} V_{assay}^{total}} C_{assay}^{unbound} * N_{in\ assay}^{hep/mp} \quad (3)$$

174 Here,  $f_{assay}^{unbound}$  refers to the unbound fraction of the compound in the assay,  $V_{assay}^{water}$  to the  
 175 volume of water in the assay (mL<sub>water</sub>) and  $V_{assay}^{total}$  to the total volume of the assay (mL<sub>assay</sub>).

176 The term  $\frac{V_{assay}^{water}}{V_{assay}^{total}}$  is the water content of the assay expressed as volume fraction, we thus  
 177 introduce the variable  $w_{assay}$  (mL<sub>water</sub>/mL<sub>assay</sub>) for this term. For simplicity we can introduce a  
 178 new variable,  $CL_{water}$ , that quantifies the volume of water in the assay that is cleared from the  
 179 freely dissolved compound either per hepatocyte and unit time or per mg S9 material or  
 180 microsomal protein and unit time ( $\frac{ml_{water}}{min * N_{hep/mp}}$ ), defined as

$$CL_{water} = \frac{CL_{assay}}{N_{in\ assay}^{hep/mp}} * \frac{V_{assay}^{water}}{f_{assay}^{unbound} V_{assay}^{total}} \quad (4)$$

181 So that eq. 3 can be written as

$$\frac{dM_{in\ assay}^{total}}{dt} = CL_{water} * C_{assay}^{unbound} * N_{in\ assay}^{hep/mp} \quad (5)$$

182 In summary,  $CL_{water}$  was obtained by normalizing the experimentally derived  $CL_{assay}$  to the  
 183 amount of metabolically active component and by accounting for the sorption effects in the  
 184 assay such that the new  $CL_{water}$  directly applies to the unbound concentration of the chemical  
 185 in the aqueous parts of assay.

186 The same mathematical procedure can be applied to describe clearance in any well-stirred  
 187 system, e.g. the liver or the whole organism, as follows: We start with the following equation  
 188 describing the change of total compound mass in the liver ( $M_{in\ liver}^{total}$ ) using the clearance in  
 189 the liver ( $CL_{liver}$ , mL<sub>liver</sub>/min) and the total compound concentration in the liver ( $C_{in\ liver}^{total}$ ,  
 190 mg/mL<sub>liver</sub>):

$$\frac{dM_{in\ liver}^{total}}{dt} = \frac{d C_{in\ liver}^{total} V_{liver}^{total}}{dt} = CL_{liver} C_{in\ liver}^{total} \quad (6)$$

191 which is analogue to eq. (1) and develop it further (as shown above for the assay) to  
 192 eventually receive

$$\frac{dM_{in\ liver}^{total}}{dt} = \frac{CL_{liver}}{N_{in\ liver}^{hep/mp}} * \frac{V_{liver}^{water}}{f_{liver}^{unbound} V_{liver}^{total}} C_{liver}^{unbound} * N_{in\ liver}^{hep/mp} \quad (7)$$

193 Here,  $N_{in\ liver}^{hep/mp}$  is the amount of metabolically active component in the liver,  $V_{liver}^{water}$  is the  
 194 volume of water in the liver (mL<sub>water</sub>),  $f_{liver}^{unbound}$  is the unbound compound fraction in the liver  
 195  $V_{liver}^{total}$  (mL<sub>liver</sub>) is the total volume of the liver and  $C_{liver}^{unbound}$  is the unbound concentration in  
 196 the aqueous parts of the liver (mg/mL<sub>water</sub>).

197 Analogously, for a whole well-stirred organism the following equation results:

$$\frac{dM_{in\ organism}^{total}}{dt} = \frac{CL_{organism}}{N_{in\ organism}^{hep/mp}} * \frac{V_{organism}^{water}}{f_{organism}^{unbound} V_{organism}^{total}} C_{organism}^{unbound} * N_{in\ organism}^{hep/mp} \quad (8)$$

198 Here,  $CL_{organism}$  (mL<sub>organism</sub>/min) is the clearance in the organism,  $N_{in\ organism}^{hep/mp}$  is the amount  
 199 of metabolically active component in the organism,  $V_{organism}^{water}$  (mL<sub>water</sub>) is the volume of water

200 in the organism,  $f_{organism}^{unbound}$  is the unbound compound fraction in the organism,  $V_{organism}^{total}$   
 201 ( $mL_{organism}$ ) is the total volume of the liver and  $C_{organism}^{unbound}$  ( $mg/mL_{water}$ ) is the unbound  
 202 compound concentration in the aqueous parts of the organism.

203 Again, we can extract an intrinsic clearance for water  $CL_{water}$  ( $\frac{mL_{water}}{min * N_{hep/mp}}$ ) from these  
 204 expressions according to

$$CL_{water} = \frac{CL_{liver}}{N_{in\ liver}^{hep/mp}} * \frac{V_{liver}^{water}}{f_{liver}^{unbound} V_{liver}^{total}} \quad (9)$$

205 for the liver, or

$$CL_{water} = \frac{CL_{organism}}{N_{in\ organism}^{hep/mp}} * \frac{V_{organism}^{water}}{f_{organism}^{unbound} V_{organism}^{total}} \quad (10)$$

206 for a whole organism. In these equations, the terms  $\frac{V_{liver}^{water}}{V_{liver}^{total}}$  and  $\frac{V_{organism}^{water}}{V_{organism}^{total}}$  are the water  
 207 contents of liver and organism expressed as volume fractions. For simplicity, we replace these  
 208 terms by the variables  $w_{liver}$  (in  $mL_{water}/mL_{liver}$ ) and  $w_{organism}$  (in  $mL_{water}/mL_{organism}$ ).

209 In all three systems (the assay, the liver and the whole organism) the water clearance  
 210 normalized to the amount of hepatocytes, microsomes or S9 material must be the same, if the  
 211 hepatocytes, microsomes or S9 material are of the same type. Hence, by equating eq. (4) and  
 212 eq. (9) we get the extrapolation scheme for extrapolation from the assay to the well-stirred  
 213 liver and by equating eq. (4) and eq. (10) we get the extrapolation scheme for extrapolation to  
 214 the well-stirred organism. Using the extrapolation to the well-stirred liver as an example, i.e.  
 215 equating eq. (4) and eq. (9), yields:

$$\frac{CL_{liver}}{N_{in\ liver}^{hep/mp}} * \frac{w_{liver}}{f_{liver}^{unbound}} = \frac{CL_{assay}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{f_{assay}^{unbound}} \quad (11)$$

216 This can be rearranged to

$$CL_{liver} = \frac{f_{liver}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{liver}} \quad (12)$$

217 Analogously, the expression for extrapolation from assay to well-stirred organism is:

$$CL_{organism} = \frac{f_{organism}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ organism}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{organism}} \quad (13)$$

218 And for extrapolation to well-stirred hepatocytes:

$$CL_{hepatocyte} = \frac{f_{hepatocyte}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ hepatocyte}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{hepatocyte}} \quad (14)$$

219 In fact, eq. (12), (13) and (14) now represent the solutions for extrapolation to the goals I),  
220 IIa) and III) described above.

221 However, the unbound fractions required in these equations can be difficult to measure. If  
222 linear equilibrium partitioning is assumed, one can proceed by rearranging the terms  
223 containing unbound fractions so that they contain only volumes and partition coefficients. The  
224 volume information is easy to achieve and the required partition coefficients can be predicted  
225 from combining the contributing sorption to proteins, lipids and water of the phase of interest  
226 (i.e. liver, organism or hepatocyte) to the overall sorption to this phase<sup>16</sup>. Accordingly, the

227 term  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  can be substituted by  $\frac{K_{assay/water}}{K_{liver/water}} * \frac{w_{liver}}{w_{assay}}$  (see SI section 3 for details of this  
228 step). Here,  $K_{assay/water}$  (mL<sub>water</sub>/mL<sub>assay</sub>) and  $K_{liver/water}$  (mL<sub>water</sub>/mL<sub>liver</sub>) are the equilibrium  
229 partition coefficients between assay and water or liver and water,  $w_{liver}$  (mL<sub>water</sub>/ mL<sub>liver</sub>) and  
230  $w_{assay}$  (mL<sub>water</sub>/mL<sub>assay</sub>) are the water contents of liver and assay.

231 In case one prefers alternative methods for the binding correction, e.g. methods additionally  
232 considering ionization of the metabolized compound and protein-facilitated uptake<sup>14, 15</sup>, this  
233 step can be adapted accordingly. Here we focus on the case of linear equilibrium partitioning

234 and substitute  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  so that eq. (12) simplifies to:

$$CL_{liver} = CL_{assay} * \frac{K_{assay/water}}{K_{liver/water}} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} \quad (15)$$

235 Analogously, the equation for extrapolation from assay to well-stirred organism simplifies to:

$$CL_{organism} = CL_{assay} * \frac{K_{assay/water}}{K_{organism/water}} * \frac{N_{in\ organism}^{hep/mp}}{N_{in\ assay}^{hep/mp}} \quad (16)$$

236 and for extrapolation to the well-stirred hepatocytes:

$$CL_{hepatocyte} = CL_{assay} * \frac{K_{assay/water}}{K_{hep/water}} * \frac{N_{in\ hep}^{hep/mp}}{N_{in\ assay}^{hep/mp}} \quad (17)$$

237 By this, equations (15), (16) and (17) also represent solutions for the extrapolation goals I),  
 238 IIa) and III). Of course, they are mathematically equivalent to the equations (12), (13) and  
 239 (14), the only difference is that they use partition coefficients instead of unbound fractions to  
 240 consider the sorption effects that differ between assay and liver, organism or hepatocytes.

241 Eq. (12) - (17) are either based on fractions unbound or on partition constants but not on a  
 242 mixture of both. However, practitioners may often be in the situation where they know  
 243 fraction unbound in the assay but only the partition constant for the system to which the  
 244 extrapolation is aiming (e.g. the liver, whole organism, hepatocytes). For these cases, one can  
 245 derive alternative forms of the IVIVE equations using 'mixed' partition information. These  
 246 equations can be found in SI section 6.

247

#### 248 **Further Extrapolation to hepatic blood clearance with flow limitation**

249 The above derivation has demonstrated that extrapolation from one well-stirred system (e.g.  
 250 the assay) to any other well-stirred system (liver, organism, hepatocytes) always follows the  
 251 same scheme. For our extrapolation scenario IIb) however, the goal is different: in IIb) we  
 252 want to arrive at the clearance of blood that passes through a well-stirred liver. Accordingly,  
 253 this clearance has to account for the effects of blood flow limitation; i.e. the situation where  
 254 the actual clearance is smaller than expected based on  $CL_{liver}$  because the transport capacity of

255 the blood for the chemical is not sufficiently high. The solution of this case can be derived by  
 256 combining the previously extrapolated liver clearance with the liver blood flow in a well-  
 257 stirred liver model as introduced by Rowland et al.<sup>9</sup> ( $k_m V_{liver}$  used by Rowland is equivalent  
 258 to  $CL_{liver}$ ):

$$CL_{blood} = \frac{Q_H * CL_{liver} K_{liver/blood}}{Q_H + CL_{liver} K_{liver/blood}} \quad (18)$$

259 As mentioned above, this clearance is commonly called hepatic clearance  $CL_{hep}$  in the  
 260 literature, but we prefer the variable  $CL_{blood}$  for better discrimination from  $CL_{liver}$ . In this  
 261 equation,  $Q_H$  is the liver blood flow in mL of blood per unit time (mL<sub>blood</sub>/min) and  $K_{liver/blood}$   
 262 is the liver-blood partition coefficient for the compound. Substituting  $CL_{liver}$  by the expression  
 263 presented in eq. (12) allows direct calculation of the hepatic clearance of blood,  $CL_{blood}$ , from  
 264 the measured  $CL_{assay}$ :

$$CL_{blood} = \frac{Q_H * \frac{f_{liver}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{liver}} * K_{liver/blood}}{Q_H + \frac{f_{liver}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{liver}} * K_{liver/blood}} \quad (19)$$

265 After suitable rearrangement (see SI section 4 for details) this equation simplifies to:

$$CL_{blood} = \frac{Q_H * \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{blood}}}{Q_H + \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} * \frac{N_{in\ liver}^{hep/mp}}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{blood}}} \quad (20)$$

266 Here,  $w_{assay}$  of course still refers to the water content of the assay (mL<sub>water</sub>/mL<sub>assay</sub>) and  
 267  $f_{assay}^{unbound}$  to the unbound compound fraction in the assay and, analogously,  $w_{blood}$  refers to the  
 268 water content of blood (mL<sub>water</sub>/mL<sub>blood</sub>) and  $f_{blood}^{unbound}$  to the unbound compound fraction in  
 269 blood. Eq. (20) yields the hepatic blood clearance  $CL_{blood}$  including potential blood flow  
 270 limitation in the unit mL<sub>blood</sub>/min. If one prefers the blood clearance expressed in a unit that is  
 271 normalized to kg of bodyweight, one has to use blood flow normalized to kg bodyweight

272 ( $Q_{H,bodyweight}$ , in mL<sub>blood</sub>/min/kg<sub>bodyweight</sub>) and one has to use the content of metabolically  
 273 active component per bodyweight instead of the absolute amount  $N_{in\ liver}^{hep/mp}$  in eq. (20). We  
 274 thus introduce the variable  $MPBW$  (in number of hepatocytes or mg of S9/microsomes per kg  
 275 bodyweight) for the content of metabolically active component per kg bodyweight. The  
 276 metabolically active component per kg bodyweight,  $MPBW$ , in humans is given by commonly  
 277 used scaling factors: in case of hepatocytes one multiplies the hepatocellularity ( $99 * 10^6$   
 278  $\frac{\text{hepatocytes}}{\text{gliver}}$ )<sup>17</sup> with the liver weight per kg bodyweight ( $20 \frac{\text{gliver}}{\text{kgbodyweight}}$ ) to get  $MPBW$ , in case  
 279 of microsomes one multiplies the microsomal protein content ( $32 \frac{\text{mgmicrosomal protein}}{\text{gliver}}$ )<sup>17</sup> with  
 280 the liver weight per kg bodyweight ( $20 \frac{\text{gliver}}{\text{kgbodyweight}}$ )<sup>3</sup> to get  $MPBW$ . Using  $MPBW$  for  
 281 calculation of blood clearance yields:

$$CL_{blood,bodyweight} = \frac{Q_{H,bodyweight} * \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{blood}}}{Q_{H,bodyweight} + \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{blood}}} \quad (21)$$

282 One has to note that the clearance calculated via eq. (21) still is a blood clearance (in  
 283 mL<sub>blood</sub>/min/kg<sub>bodyweight</sub>) and not a whole-body clearance (mL<sub>organism</sub>/min), i.e.  
 284  $CL_{blood,bodyweight}$  describes the effect of hepatic metabolism on a compound concentration in  
 285 blood. Note, that in the literature, the terms  $CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}}$  and  $\frac{f_{blood}^{unbound}}{f_{assay}^{unbound}}$  are often  
 286 substituted by the shorter but potentially unclear variable names ‘*in vivo* intrinsic clearance’  
 287 and ‘ $f_u$ ’<sup>5</sup>.

288 Of course, one can also create an alternative version of the equation for calculation of hepatic  
 289 blood clearance with flow limitation that uses partition coefficients instead of unbound  
 290 fractions. Details for the derivation of this alternative version can be found in SI section 5.  
 291 The resulting equation for hepatic blood clearance in the unit mL<sub>blood</sub>/min is:

$$CL_{blood} = \frac{Q_H * CL_{assay} \frac{K_{assay/water} N_{in\ liver}^{hep/mp}}{K_{blood/water} N_{in\ assay}^{hep/mp}}}{Q_H + CL_{assay} \frac{K_{assay/water} N_{in\ liver}^{hep/mp}}{K_{blood/water} N_{in\ assay}^{hep/mp}}} \quad (22)$$

292 and for the hepatic blood clearance in the unit  $mL_{blood}/min/kg_{bodyweight}$ :

$$CL_{blood,bodyweight} = \frac{Q_{H,bodyweight} * CL_{assay} \frac{K_{assay/water} MPBW}{K_{blood/water} N_{in\ assay}^{hep/mp}}}{Q_{H,bodyweight} + CL_{assay} \frac{K_{assay/water} MPBW}{K_{blood/water} N_{in\ assay}^{hep/mp}}} \quad (23)$$

293

## 294 RESULTS & DISCUSSION

295 Our stepwise derivation of the extrapolation mathematics yielded specific equations for all  
 296 desired extrapolation goals: extrapolation from the assay clearance to the clearance in other  
 297 well-stirred systems like hepatocytes, liver or a whole organism and extrapolation from the  
 298 assay clearance to the clearance of blood that flows through a well-stirred liver. For better  
 299 overview, Table 1 shows all extrapolation goals with the numbers of the corresponding final  
 300 equations at a glance:

301 Table 1: Overview of extrapolation goals and corresponding equations for two types of sorption information.

sorption information in form of	extrapolation to			
	I) whole-body clearance	IIa) organ clearance	IIb) hepatic blood clearance	III) hepatocyte clearance
known unbound fraction	(13)	(12)	(20) or normalized to bodyweight with (21)	(14)
known partition coefficient	(16)	(15)	(22) or normalized to	(17)

			bodyweight with (23)	
--	--	--	-------------------------	--

302 In the supporting information of this manuscript, the generalized forms of the here derived  
303 equations for extrapolation between any two well-mixed systems are presented and a guide  
304 for equation selection is given in table S1 (SI section 1).

305 As described in the introduction, the extrapolation schemes available in the literature target  
306 only the scenario of extrapolation to the clearance of blood that flows through a well-stirred  
307 liver<sup>1, 4, 8, 13, 15</sup>. Comparison of the results above with the extrapolation schemes available in  
308 the literature is difficult, because the used variables differ in their normalizations and units  
309 and derivations of the used equations are often not provided in detail. One of the first  
310 extrapolation schemes that includes binding correction and that is frequently cited was  
311 presented by Obach<sup>13</sup> yielding three different equations for extrapolation to hepatic blood  
312 clearance in a well-stirred liver. These three extrapolation procedures presented by Obach  
313 differ in the way in which binding correction is performed. Among these, the procedure that  
314 considers unspecific binding in the assay as well unspecific binding *in vivo* comes closest to  
315 our extrapolation procedure. The equation that Obach provides for this extrapolation  
316 procedure is:

$$CL_{blood, body\ weight}^{Obach} = \frac{Q_{H, body\ weight} * \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL'_{int}}{Q_{h, body\ weight} + \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL'_{int}} \quad (24)$$

317 According to Obach, this equation yields a blood clearance in mL<sub>blood</sub>/min/kg<sub>bodyweight</sub> that is  
318 calculated by using the hepatic blood flow  $Q_{H, body\ weight}$  normalized to bodyweight and the  
319 scaled *in vivo* clearance  $CL'_{int}$  normalized to bodyweight. Scaling and normalization of  $CL'_{int}$   
320 to bodyweight is achieved via multiplication of the measured assay clearance that is

321 normalized to mg of microsomal protein in the assay with the content of metabolically active  
 322 component per kg bodyweight ( $MPBW = 32 \frac{\text{mg}_{\text{microsomal protein}}}{\text{g}_{\text{liver}}} * 20 \frac{\text{g}_{\text{liver}}}{\text{kg}_{\text{bodyweight}}}$ ):

$$CL'_{int} = \frac{CL_{assay}}{N_{in\ assay}^{hep/mp}} * MPBW \quad (25)$$

323 Accordingly, eq. (24) can be rewritten to:


$$CL_{blood, body\ weight}^{Obach} = \frac{Q_{H, body\ weight} * \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}}}{Q_{H, body\ weight} + \frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}}} \quad (26)$$

324 Eq. (26) representing the Obach approach can be directly compared to our eq. (21) because  
 325 both are supposed to describe the same extrapolation scheme. The comparison reveals,  
 326 though, that they are not exactly equivalent. Our eq. (21) contains a ratio of water contents  
 327 that is not included in the Obach equation and the resulting units are different in both  
 328 equations. The term  $\frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}} * \frac{w_{assay}}{w_{blood}}$  in our eq. (21) has units of  
 329  $\text{mL}_{\text{blood}}/\text{min}/\text{kg}_{\text{bodyweight}}$  as one would expect for blood clearance, whereas the corresponding  
 330 term  $\frac{f_{blood}^{unbound}}{f_{assay}^{unbound}} * CL_{assay} \frac{MPBW}{N_{in\ assay}^{hep/mp}}$  in eq. (26) from Obach has units of  $\text{mL}_{\text{assay}}/\text{min}/\text{kg}_{\text{bodyweight}}$   
 331 which implies that this term represents an assay clearance. Numerically, however, both  
 332 equations produce very similar numbers, because the term  $\frac{w_{assay}}{w_{blood}}$  by which both equations  
 333 differ is rather close to unity. More precisely, the water content of blood is  $0.8 \text{ mL}_{\text{water}}/\text{mL}_{\text{blood}}$   
 334 <sup>18</sup> and the water content of the assay will always be close to  $1 \text{ mL}_{\text{water}}/\text{mL}_{\text{assay}}$ . Accordingly,  
 335 the ratio of the water contents,  $\frac{w_{assay}}{w_{blood}}$ , roughly yields 1.25 and the numerical difference  
 336 between both equations thus won't exceed 25 %. This is not sufficient to explain the  
 337 discrepancies that have been found in the past (see introduction). These might rather have  
 338 their cause in the neglect of extrahepatic metabolism.

339 As an amendment to our equations shown above we have also set out to derive the  
340 extrapolation scheme based on rate constants instead of clearance and using an alternative  
341 starting point. This derivation (shown in SI section 6) is in fact shorter and – in our opinion –  
342 easier to understand intuitively than the one given in the main text that uses the clearance  
343 concept. The result derived from this alternative approach at the end is identical to the one  
344 shown above in eqs. (15), (16) and (17). Plausibility of the alternative derivation can be  
345 checked via a thought experiment for chemicals with a small unbound fraction (SI section 7).  
346 The fact that the alternative approach (SI section 6) for solving the extrapolation goals I-III  
347 gives the same results as in our main text and the plausibility check (SI section 7) was  
348 successful provides assurance that our presented extrapolation schemes are mathematically  
349 correct.

350 **Sensitivity Analysis.** Equations (12) - (14) constitute the central equations for IVIVE for  
351 those three scenarios that do not account for blood flow limitation (see Fig.1). Obviously, any  
352 error in the *in vitro* clearance value,  $CL_{assay}$ , will proportionally affect the extrapolated  
353 clearance value. For the most part, this error in the *in vitro* data is probably a systematic one  
354 that is connected to the quality and representativeness of the hepatocytes, S9 material or  
355 microsomes. If one compares normalized *in vitro* clearance values from different labs for  
356 given chemicals one finds quite high discrepancies. For pyrene Lee et al.<sup>19</sup> reported an assay  
357 clearance normalized to the amount of S9 (from trout liver) in assay of 0.4 mL/h/mg<sub>S9</sub>,  
358 whereas Nichols reported a value of 10.1 mL/h/mg<sub>S9</sub><sup>20</sup> and for benzo(a)pyrene Han et al.<sup>21</sup>  
359 published a value of 0.07 mL/h/mg<sub>S9</sub>, whereas Nichols determined a value of 16.7 mL/h/mg<sub>S9</sub>  
360<sup>20</sup>. Besides the *in vitro* metabolic information, input information on the amount of  
361 metabolically active components, on the unbound fractions and on the relative water contents  
362 of the assay and the target system (whole organism, liver or hepatocytes) is required. The  
363 amount of metabolically active components and the relative water contents are either well-  
364 known from the literature<sup>3, 17, 18</sup> or set by the investigator so that this information should have

365 high accuracy (the relative error is likely below 5%) and the error in the extrapolated  
 366 clearance resulting from the uncertainties of these values is below 20 %. Errors in the  
 367 information on fraction unbound can be considerably higher if estimated values are used due  
 368 to the high uncertainties in the respective partition coefficients. However, in the two extreme  
 369 situations (i.e. fraction unbound is very high or very low) the term  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  is not determined  
 370 by the partition coefficients of the chemical anymore but by the quotient of either the relative  
 371 aqueous volumes in assay and organism/liver/hepatocytes or by relative volumes of sorbing  
 372 tissue in assay and organism/liver/hepatocytes. Hence, only for chemicals in a moderate range  
 373 of hydrophobicity the accurate knowledge of the partition coefficient is crucial for the quality  
 374 of the term  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  and thus for the quality of the whole extrapolation result. This qualitative  
 375 conclusion can be supported by more quantitative information if one calculates  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  based  
 376 on the log of the octanol-water partition coefficients,  $\log K_{ow}$ , of the chemicals (for details see  
 377 SI section 9). In Fig. 2 we show the results for such a calculation for a range of octanol-water  
 378 partition coefficients representing chemicals with different hydrophobicity. To include a  
 379 calculation of the propagated error we assumed that the actual partition coefficients might be  
 380 a factor 3 higher or lower than the value used and plotted the results against  $\log K_{ow}$  (Figure  
 381 2).



382  
 383

384 Figure 2: Uncertainties in the fractions unbound in assay and liver estimated using octanol-water partition coefficients (part  
385 a) and the resulting relative error in  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  (part b).

386 Figure 2 indicates that the fractions unbound in assay and liver are most sensitive to potential  
387 errors for chemicals with  $\log K_{OW}$  between 0 and 3 (Figure 2a). Accordingly, the relative  
388 uncertainty in the term  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  is biggest for chemicals with  $\log K_{OW}$  between 0 and 3 as  
389 well (Figure 2b). Information on the relevant partition coefficients of these chemicals thus  
390 needs to be known quite reliably or measurements of the fractions unbound are needed. For  
391 chemicals with  $\log K_{OW}$  lower than 0 or higher than 3, the relative uncertainty in  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$   
392 becomes small and the accuracy of the partition coefficient used to estimate  $\frac{f_{liver}^{unbound}}{f_{assay}^{unbound}}$  is not  
393 relevant for the accuracy of the extrapolation result.


394 For the last extrapolation scenario, the extrapolation to hepatic blood clearance considering  
395 blood flow limitation, one needs to discriminate the not-blood flow-limited from the blood  
396 flow-limited case when discussing potential errors. For the first case, the extrapolation  
397 scheme simplifies to the scenarios discussed above. For the latter case, the blood flow-limited  
398 case, the extrapolation result simply approaches the blood flow rate and thus becomes  
399 insensitive to errors resulting from the extrapolation procedure.

400

#### 401 **Evaluation of perfused liver data**

402 The presented toolbox for IVIVE offers solutions for various extrapolation goals. For a  
403 comparison of extrapolated clearances with measured clearances the level of the hepatic blood  
404 clearance determined in isolated perfused liver experiments is most suitable. In these  
405 experiments, the pure metabolic capacity of the liver is determined because other factors like  
406 extrahepatic metabolism or elimination via urine are excluded. Here, we extrapolate *in vitro*  
407 data from trout S9 for six PAHs (polycyclic aromatic hydrocarbons) to the level of hepatic

408 blood clearances and compare the extrapolation results with the clearances determined in  
 409 isolated perfused trout liver experiments published by Nichols et al.<sup>20</sup>. In this study, isolated  
 410 trout livers were perfused with perfusates containing the PAHs and either 1 mg/mL bovine  
 411 serum albumin (BSA) or 10 mg/mL BSA. Via analysis of the PAH concentrations in the  
 412 perfusate, hepatic blood clearance or, more precisely (because perfusate instead of blood is  
 413 used in the experiments), hepatic perfusate clearance was determined. For comparison, we  
 414 extrapolated *in vitro* data for the same PAHs to hepatic perfusate clearance using eq. (20) (for  
 415 details see SI section 10). By using eq. (20) blood flow limitation is considered in the  
 416 extrapolation. Additionally we calculated a second set of clearances where blood flow  
 417 limitation is neglected (for details see SI section 10). The results are shown in Figure 3, a  
 418 complete overview of the used data can be found in SI section 10.



419  
 420 Figure 3: Comparison of predicted clearances with observed clearances from isolated perfused liver experiments for six  
 421 PAHs. Part a) shows results for experiments with 1 mg/ml BSA in perfusate, part b) shows results for experiments with 10  
 422 mg/ml in perfusate.

423 In Figure 3, the observed log CL<sub>perfusate</sub> is plotted versus the predicted log CL<sub>perfusate</sub>. The 1:1  
 424 line is shown for orientation. The triangles represent the extrapolation results when blood  
 425 flow limitation is not considered; the circles represent extrapolation results when blood flow  
 426 limitation is accounted for. For the best-metabolized PAHs (highest observed CL<sub>perfusate</sub>),  
 427 hepatic metabolism appears to be blood flow limited because the extrapolation results  
 428 neglecting blood flow greatly exceed (up to 2 log-units) the extrapolation results considering

429 blood flow; and the latter are in fact in good agreement with the measured values. The largest  
430 discrepancy between measured and extrapolated  $CL_{\text{perfusate}}$  occurs for naphthalene that lies in  
431 the hydrophobicity range ( $\log K_{\text{OW}} = 3.3$ ) where the highest error from estimated unbound  
432 fractions must be expected (see Figure 2b). Another explanation for the remaining  
433 discrepancies could be an altered metabolic capacity of the used S9-material in the *in vitro*-  
434 experiments compared to the intact liver used in perfused liver experiments. Such a  
435 systematic error could not be corrected for by the extrapolation scheme but could be avoided  
436 by optimization of the *in vitro* test system.

### 437 **Conclusion**

438 The here derived set of equations presents solutions for *in vitro-in vivo* extrapolation from all  
439 kinds of *in vitro* assays (hepatocytes, S9-material, microsomes) to various *in vivo* scales  
440 (whole organism, liver, blood, hepatocytes). With this extrapolation toolbox at hand it should  
441 now become easy to pick out the appropriate extrapolation pathway for any practical problem  
442 of *in vivo – in vitro* extrapolation for hepatic transformation kinetics.

443

### 444 **ACKNOWLEDGEMENTS**

445 The authors thank Nadin Ulrich for helpful discussions.

446

### 447 **SUPPORTING INFORMATION**

448 A guide for equation selection, a comparison of the variable names used here and used in the  
449 literature, detailed derivations of the presented equations for extrapolation, an alternative  
450 derivation of the presented IVIVE scheme using rate constants instead of clearances as an  
451 alternative starting point, a thought experiment as simple plausibility check, a derivation for  
452 inclusion of blood flow limitation and details for the calculations for the sensitivity analysis  
453 and the perfused liver data are shown in a supporting PDF file.

454

455 **REFERENCES**

- 456 (1) Rane, A., Wilkinson, G. R., and Shand, D. G. (1977) Prediction of hepatic extraction  
457 ratio from *in vitro* measurement of intrinsic clearance. *Journal of Pharmacology and*  
458 *Experimental Therapeutics* 200, 420-424.
- 459 (2) Chiba, M., Ishii, Y., and Sugiyama, Y. (2009) Prediction of hepatic clearance in  
460 human from *in vitro* data for successful drug development. *Aaps J* 11, 262-276.
- 461 (3) Obach, R. S. (1997) Nonspecific binding to microsomes: impact on scale-up of *in*  
462 *vitro* intrinsic clearance to hepatic clearance as assessed through examination of  
463 warfarin, imipramine, and propranolol. *Drug Metabolism and Disposition* 25, 1359-  
464 1369.
- 465 (4) Obach, R. S. (1999) Prediction of human clearance of twenty-nine drugs from hepatic  
466 microsomal intrinsic clearance data: an examination of *in vitro* half-life approach and  
467 nonspecific binding to microsomes. *Drug Metabolism and Disposition* 27, 1350-1359.
- 468 (5) Nichols, J. W., Huggett, D. B., Arnot, J. A., Fitzsimmons, P. N., and Cowan-Ellsberry,  
469 C. E. (2013) Toward improved models for predicting bioconcentration of well-  
470 metabolized compounds by rainbow trout using measured rates of *in vitro* intrinsic  
471 clearance. *Environmental Toxicology and Chemistry* 32, 1611-1622.
- 472 (6) Brian Houston, J., and Carlile, D. J. (1997) Prediction of hepatic clearance from  
473 microsomes, hepatocytes, and liver slices. *Drug Metabolism Reviews* 29, 891-922.
- 474 (7) Jones, H., and Houston, J. B. (2004) Use of the substrate depletion approach for  
475 determining *in vitro* metabolic clearance: time dependencies in hepatocyte and  
476 microsomal incubations. *Drug Metabolism and Disposition* 32, 973-982.
- 477 (8) Poulin, P., and Haddad, S. (2013) Toward a new paradigm for the efficient *in vitro*-*in*  
478 *vivo* extrapolation of metabolic clearance in humans from hepatocyte data. *Journal of*  
479 *Pharmaceutical Sciences* 102, 3239-3251.
- 480 (9) Rowland, M., Benet, L. Z., and Graham, G. G. (1973) Clearance concepts in  
481 pharmacokinetics. *Journal of Pharmacokinetics and Biopharmaceutics* 1, 123-136.
- 482 (10) Stadnicka-Michalak, J., Weiss, F. T., Fischer, M., Tanneberger, K., and Schirmer, K.  
483 (2018) Biotransformation of benzo[a]pyrene by three rainbow trout (*Onchorhynchus*  
484 *mykiss*) cell lines and extrapolation to derive a fish bioconcentration factor.  
485 *Environmental Science & Technology* 52, 3091-3100.
- 486 (11) Larisch, W., Brown, T. N., and Goss, K.-U. (2017) A toxicokinetic model for fish  
487 including multiphase sorption features. *Environmental Toxicology and Chemistry* 36,  
488 1538-1546.

- 489 (12) Krause, S., and Goss, K.-U. (2018) The impact of desorption kinetics from albumin on  
490 hepatic extraction efficiency and hepatic clearance: a model study. *Archives of*  
491 *Toxicology* 92, 2175-2182.
- 492 (13) Obach, R. S. (1996) The importance of nonspecific binding in *in vitro* matrices, its  
493 impact on enzyme kinetic studies of drug metabolism reactions, and implications for  
494 *in vitro-in vivo* correlations. *Drug Metabolism and Disposition* 24, 1047-1049.
- 495 (14) Poulin, P., Kenny, J. R., Hop, C. E. C. A., and Haddad, S. (2012) *In vitro-in vivo*  
496 extrapolation of clearance: modeling hepatic metabolic clearance of highly bound  
497 drugs and comparative assessment with existing calculation methods. *Journal of*  
498 *Pharmaceutical Sciences* 101, 838-851.
- 499 (15) Berezhkovskiy, L. M. (2011) The corrected traditional equations for calculation of  
500 hepatic clearance that account for the difference in drug ionization in extracellular and  
501 intracellular tissue water and the corresponding corrected PBPK equation. *Journal of*  
502 *Pharmaceutical Sciences* 100, 1167-1183.
- 503 (16) Endo, S., Brown, T. N., and Goss, K.-U. (2013) General model for estimating partition  
504 coefficients to organisms and their tissues using the biological compositions and  
505 polyparameter linear free energy relationships. *Environmental Science & Technology*  
506 47, 6630-6639.
- 507 (17) Zoe, E. B., Martin, K. B., Philip, H. B., Alan, R. B., David, J. C., Robert, J. E.,  
508 Houston, J. B., Brian, G. L., John, C. L., Olavi, R. P., Geoffrey, T. T., and Amin, R.-  
509 H. (2007) Scaling factors for the extrapolation of *in vivo* metabolic drug clearance  
510 from *in vitro* data: reaching a consensus on values of human microsomal protein and  
511 hepatocellularity per gram of liver. *Current Drug Metabolism* 8, 33-45.
- 512 (18) Snyder, W., Cook, M., Nasset, E., Karhausen, L., Howells, G., and Tipton, I. (1975)  
513 ICRP Publication 23: report of the task group on reference man, International  
514 Commission on Radiological Protection.
- 515 (19) Lee, Y.-S., Lee, D. H. Y., Delafoulhouze, M., Otton, S. V., Moore, M. M., Kennedy,  
516 C. J., and Gobas, F. A. P. C. (2014) *In vitro* biotransformation rates in fish liver S9:  
517 Effect of dosing techniques. *Environmental Toxicology and Chemistry* 33, 1885-1893.
- 518 (20) Nichols, J. W., Hoffman, A. D., ter Laak, T. L., and Fitzsimmons, P. N. (2013)  
519 Hepatic clearance of 6 polycyclic aromatic hydrocarbons by isolated perfused trout  
520 livers: prediction from *in vitro* clearance by liver S9 fractions. *Toxicological Sciences*  
521 136, 359-372.

522 (21) Han, X., Nabb, D. L., Yang, C.-H., Snajdr, S. I., and Mingoia, R. T. (2009) Liver  
523 microsomes and S9 from rainbow trout (*Oncorhynchus mykiss*): Comparison of basal-  
524 level enzyme activities with rat and determination of xenobiotic intrinsic clearance in  
525 support of bioaccumulation assessment. *Environmental Toxicology and Chemistry* 28,  
526 481-488.

527

528

529